Crohn's Colitis Cure

What Crohn's Colitis Cure does

Crohn's Colitis Cure (CCCure) is an Australian non-profit charity founded in 2011 and headquartered in Pyrmont, NSW, focused on inflammatory bowel disease (IBD) care and research. The organisation operates a cloud-based software platform centred on CCCare — described as the world's first IBD-specific electronic medical record and patient management system — which is licensed to over 20 healthcare facilities across Australia and New Zealand and used by more than 400 clinicians to document care, capture real-world data, and feed a longitudinal research database. The platform is complemented by IBD-PERFECT, a public quality-benchmarking tool, and a Mobile Co-Care App for iOS and Android anticipated to launch in May 2026.

The underlying technology stack combines a cloud-based SaaS EMR, an integrated patient-facing mobile application, and a longitudinal research database described as the world's richest structured, multinational IBD registry, with 17,000+ patient records. Differentiated features include portable lifelong health records, dynamic care plans, real-time symptom tracking with alerts, automated clinic letter generation, integrated mental health support, and de-identified data processing for research. The data environment is supported by expert analytics at Adelaide University's Australian Institute for Machine Learning and is positioned as AI-ready for advanced modelling.

CCCure is funded through three streams: individual tax-deductible donations (it receives no government funding), CCCare platform licensing to healthcare facilities, and commercial data analytics subscriptions provided to pharmaceutical and medical services companies such as AbbVie, Takeda, Johnson & Johnson, Ferring Pharmaceuticals, and Dr. Falk. The organisation is led by CEO Bill Petch and chaired by Professor Jane M Andrews, with core grant support from The Leona M. and Harry B. Helmsley Charitable Trust, and operates as a registered Australian charity (ABN 85 154 588 717).

Name

Crohn's Colitis Cure

Legal name

Crohn's Colitis Cure

Website

https://c-c-cure.org

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Crohn's Colitis Cure is an Australian non-profit charity operating CCCare, the world's first IBD-specific electronic medical record, licensed to 20+ care sites across Australia and New Zealand with a 17,000+ patient research database and a patient-facing mobile app launching May 2026.

Ownership category

akta.pro rank

Product category

Healthcare Clinical Software

NAICS

Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

Inflammatory Bowel Disease (IBD) Care (HLAKAEAD)

akta.pro secondary industries

Patient Relationship Management (PRM) & CRM for Provider Growth (Marketing/Outreach) (HLACAEAO), Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)

Keywords

• IBD care platform
• Electronic medical records
• Clinical data analytics
• Patient management software
• Real-world evidence data

Headquarters

HQ city

Pyrmont

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Donations: CCCure receives no government funding and relies on donations from individuals. As a registered Australian charity with tax-deductible gift recipient status, all donations are tax deductible in Australia.
2. Data Analytics Subscriptions: Organisations can partner by subscribing to data analytics services, driving innovation and improving outcomes in IBD care. De-identified data is supplied on a commercial basis to commercial organisations including pharmaceutical and medical services companies.
3. CCCare Platform Licensing: The CCCare platform is licensed to healthcare facilities. Healthcare organisations can inquire about CCCare license to implement the platform at their sites.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Crohn's Colitis Cure develops and operates CCCare, an IBD-specific electronic medical record and patient management platform licensed to healthcare facilities across Australia and New Zealand. The organization also runs a longitudinal IBD data registry, offers data analytics services to commercial partners, and operates IBD-PERFECT, a public benchmarking platform for IBD care quality. A patient-facing Mobile Co-Care App is in development with anticipated launch in May 2026.

Product overview

CCCure offers a unified platform ecosystem comprising three interconnected products: CCCare (world's first IBD-specific electronic medical record and patient management platform for clinicians), the Mobile Co-Care App (patient-facing mobile application for portable, personalised care), and IBD-PERFECT (public reporting for quality benchmarking). All three products feed into the CCCure Data Environment—a rich, continuously-updating data registry that supports real-world evidence generation and AI-ready research capabilities. The architecture connects patients, clinicians, researchers, and policy makers through a shared data system, with 20 care sites, 400+ healthcare professionals, and 17,000+ patient records.

Differentiator

Problem solved

Functional benefit

Brands

• CCCare: The world's first IBD-specific electronic medical record and care management platform that connects patients and clinicians while contributing to a longitudinal research database.
• Mobile Co-Care App
• IBD-PERFECT

Products and services

• CCCare Platform

Quantifiable outcome

• 20+ care sites using the platform
• +2 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature10 records

Partnerships

16 partnerships are on record, tiered core and minor.

• Crohn's & Colitis AustraliacoreStrategic or Co-development PartnerPatient advocacy organisation representing people with IBD in Australia. Listed as partner in care on CCCure website.
• Crohn's Colitis FoundationcoreStrategic or Co-development PartnerMajor US-based IBD patient organisation. Partnership indicates international collaboration in IBD care.
• Crohn's & Colitis New ZealandcoreStrategic or Co-development PartnerPatient advocacy organisation representing people with IBD in New Zealand. Supports bi-national reach of CCCare platform.
• Gastroenterological Society of Australia (GENCA)coreStrategic or Co-development PartnerProfessional gastroenterology society in Australia. Key professional partner for clinical engagement.
• IBD Nurses AustraliacoreStrategic or Co-development PartnerProfessional body representing IBD nursing specialists in Australia.
• AbbVieminorStrategic or Co-development PartnerPharmaceutical company partner supporting IBD care initiatives.
• TakedaminorStrategic or Co-development PartnerPharmaceutical company partner supporting IBD care initiatives.
• Johnson & JohnsonminorStrategic or Co-development PartnerPharmaceutical company partner supporting IBD care initiatives.
• Ferring PharmaceuticalsminorStrategic or Co-development PartnerPharmaceutical company partner supporting IBD care initiatives.
• Adelaide UniversitycoreStrategic or Co-development PartnerResearch collaborator providing expert analytics support through Australian Institute for Machine Learning.
• Australian National UniversitycoreStrategic or Co-development PartnerResearch collaborator listed on research page.
• Ingham InstitutecoreStrategic or Co-development PartnerResearch collaborator in medical research.
• Swinburne UniversitycoreStrategic or Co-development PartnerResearch collaborator listed on research page.
• Liverpool Hospital Gastro DeptcoreStrategic or Co-development PartnerClinical care site and research collaborator - home to one of Australia's major IBD services led by Prof Susan Connor.
• Royal Brisbane and Women's Hospital IBD UnitcoreStrategic or Co-development PartnerClinical care site and research collaborator.
• NSW HealthcoreStrategic or Co-development PartnerGovernment health authority partner supporting IBD care delivery.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Trellus Health: Digital health company focused specifically on inflammatory bowel disease (Crohn's and ulcerative colitis), offering a platform combining patient engagement, coaching, and data-driven care. Closest direct peer to CCCure in terms of IBD-specific, digitally enabled care delivery.
• MyHealthTeams: Operates condition-specific social and data networks including MyCrohnsAndColitisTeam for the IBD community. Comparable as a patient-facing IBD community and real-world data platform with pharma partnership monetisation.
• Iterative Health: Gastroenterology-focused health technology company combining AI-enabled endoscopy tools with clinical trial technology and real-world data for GI practices. Comparable as a specialty GI-focused digital health and data company.

Broad incumbents

• ModMed: Specialty-specific EHR (including gastroenterology) with built-in practice management, patient engagement, and analytics. Comparable as a competing specialty EMR incumbent that gastroenterology practices could choose over CCCare.
• Flatiron Health: Oncology-focused real-world evidence platform combining EHR-linked clinical data with research and pharma analytics offerings. Closely comparable business model (specialty clinical data + pharma RWE) but in oncology rather than IBD.
• Epic Systems: Dominant US-based EHR with specialty modules and large patient data assets. Broad incumbent whose entry into IBD-specific workflows could pressure CCCure's specialty differentiation.
• Athenahealth: Cloud-based EHR and patient engagement platform serving specialty practices including gastroenterology. Comparable as a cloud-delivered ambulatory EMR with patient portal and analytics layers.
• IQVIA: Global clinical research and real-world evidence provider combining data, technology, and CRO services for pharma. Comparable as a competing large-scale source of pharma RWE and IBD-related clinical data partnerships.

Emerging players

• TriNetX: Global real-world evidence and clinical trial feasibility network using de-identified EHR data from health systems. Comparable as a competing specialty data and pharma RWE platform, though broader across therapeutic areas.

Others

• Phreesia: Patient intake, engagement, and scheduling platform used across specialties including gastroenterology. Comparable as an adjacent patient-engagement layer that gastroenterology practices may bundle alongside their EMR.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/crohn-s-colitis-cure

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Crohn's Colitis Cure